ClinicalTrials.gg
RecruitingNCT07424326EXTEND-PVIUpdated Sep 24, 2026

Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation

An interventional study of PVI-plus and PVI-only in Atrial Fibrillation (AF), sponsored by Charles University, Czech Republic. Recruiting at 4 sites in Czechia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Charles University, Czech Republic · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Atrial Fibrillation by Charles University, Czech Republic — 13 open to participants now, 13 under way, 3 of them phase 3. Atrial Fibrillation · Charles University, Czech Republic.

Started
2026
with 1 other
No phase
3 of 20
1 open now
Primary completion
2029-12
later than 12 of 12 live
Registered
19th of 20
by date

Among the 20 studies in Atrial Fibrillation by Charles University, Czech Republic, this one is one of 2 that started in 2026, is one of 3 with no phase, reaches primary completion later than 12 of the 12 other live ones, and was the 19th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

13 of the 20 studies in Atrial Fibrillation by Charles University, Czech Republic are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Atrial Fibrillation by Charles University, Czech Republic, or all of them as a file.
02

Study summary

The aim is to determine the effect of extended ablation (pre-specified linear PF/RF lesion set) in addition to PVI in symptomatic persistent AF patients on AF/AT/AFL recurrence. The study is designed as multicenter, randomized trial. Eligible patients are patients with persistent AF (but not long-standing persistent AF) planned for a first-ever AF ablation procedure. Patients will be randomly assigned 1:1 either to: i) PVI-only, or ii) PVI-plus arms. Patients in both groups will undergo catheter ablation using an ablation system capable of performing PF and RF ablation (Sphere-9, Affera, Medtronic). Patients randomized to the PVI-only arm will undergo only PVI. Patients randomized to the PVI-plus arm will undergo PVI plus linear lesions (roof, bottom line, lateral or anterior MI line, and septal line in the LA; intercaval line and cavotricuspid line in the RA). The primary endpoint will be freedom from recurrent AF/AT/AFL, assessed as time-to-first recurrence in the period of 12 months after randomization (post 2-month blanking period). Secondary clinical endpoints will be 1) 1) AF/AT/AFL burden during the first 12 months after randomization, 2) 2) Quality of life according to the AFEQT questionnaire score at 12 months, 3) 3) AF/AFL/AT-related outcomes (hospitalization or emergency visits), 4) MACE defined as cardiovascular death, stroke, myocardial infarction, or hospitalization for heart failuree, 5) A composite of pre-specified, procedure-related SAE within 7 days after the procedure, including clinically relevant delayed SAEs adjudicated as related to the index ablation procedure. Secondary endpoints will be evaluated throughout the entire (minimum 12-month) follow-up period.

Read the detailed description

BACKGROUND The cornerstone of catheter ablation for AF is pulmonary vein (PV) isolation (PVI). PVI alone is highly effective in patients with paroxysmal AF; however, its efficacy is lower in patients with non-paroxysmal AF (persistent and long-standing persistent). For this reason, additional ablation strategies have been developed and investigated in patients with non-paroxysmal AF. However, results from randomized catheter-based studies comparing PVI alone with extended ablation strategies combining PVI with additional linear lesions have been inconsistent. While some studies showed no improvement in sinus rhythm (SR) maintenance with the addition of linear lesions compared with PVI alone, other studies demonstrated superiority of an extensive ablation approach, including linear lesions over PVI alone. A key determinant of success in these studies is the completeness of the ablation lesion set. . In studies using radiofrequency (RF) energy alone, such as the STAR AF II trial, all planned linear ablation lesions were completed in only 74% of patients during the procedure. Moreover, in the CAPLA study, comparing PVI alone with PVI combined with adjunctive left atrial (LA) posterior wall isolation using roof and inferior lines, posterior wall reconnections were present in 75% of patients. However, the results of older catheter ablation studies that relied solely on RF energy cannot be directly extrapolated to contemporary procedures performed using PF energy or combined PF/RF systems that also enable simultaneous endocardial mapping and thus reliable identification of conduction gaps and completion of ablation lesions. The markedly higher efficacy of these newer energy modalities and their combinations raises the question of whether highly effective comprehensive endocardial ablation, including linear lesions, will be associated with superior sinus rhythm maintenance compared with PVI alone.

The aim of this study is therefore to compare PVI-alone with an extended ablation strategy (PVI plus linear lesions) in patients with persistent AF, using a technology that enables ablation with both PF and RF energy and 3D mapping.

STUDY DESIGN Prospective, randomized controlled trial that will be conducted at 4 sites in the Czechia.

STUDY POPULATION The study focuses on patients with persistent AF as defined in recent ESC guidelines (i.e., with ≥2 AF episodes; ≥1 episode with a duration of >7 days) who are referred the catheter ablation in accordance with the indication criteria outlined in these guidelines.

Inclusion criteria:

  • symptomatic persistent AF
  • ≥2 episodes of persistent AF in the last 24months, of which ≥1 episode of persistent AF in the last 12 months; or ongoing AF lasting >7 days at the time of screening
  • LAd ≥42 mm
  • signed informed consent

Exclusion criteria:

  • first-manifested AF
  • paroxysmal AF, long-standing persistent AF, permanent AF
  • AF of secondary cause (e.g., hyperthyroidism)
  • any previous LA ablation
  • severe valvular disease (mitral valve insufficiency ≥3+, moderate or severe aortic stenosis) or history of valvular surgery or intervention
  • left ventricular ejection fraction ≤40%
  • pulmonary hypertension (estimated systolic pulmonary artery pressure ≥40 mm Hg)
  • symptomatic coronary artery disease
  • pregnancy
  • LAd ≥55 mm
  • body mass index ≥40 kg/m2
  • age \< 18 years, or ≥80 years
  • chronic kidney disease stage 3b or higher
  • general contraindications of catheter ablation
  • contraindication to anticoagulation
  • life expectancy \<2 years due to other comorbidities

RANDOMIZATION AND MASKING Patients will be randomized to the PVI-plus or PVI-only arm. Operators, personnel involved in the procedure, and staff participating in the patient´s clinical follow-up will not be blinded to the treatment allocation.

ECG monitoring will be performed outside the participating centres, and the technicians and physicians analyzing the ECG recordings will be fully blinded to the patient's assignment.

ELECTROPHYSIOLOGICAL STUDY AND ABLATION PROCEDURE Ablation will be performed using an ablation system that enables endocardial mapping and delivery of both PF and RF energy (Affera, Medtronic, USA). The aim of ablation therapy in the PVI-only arm will be PVI alone. The objective in the PVI-plus arm will be, in addition to PVI, the deployment of a comprehensive ablation lesion set designed to block major atrial reentry circuits, including the roof and bottom lines, perimitral (lateral or anterior) line, septal line in the left atrium, and CTI line with intercaval line in the right atrium.

OUT-PATIENT FOLLOW-UP AND BLANKING PERIOD Starting on the day of randomization, out-patient follow-up visits will be scheduled at 2, 6, and 12 months. The first 2 months will serve as a blanking period. In the event of AF/AT/AFL recurrence during the blanking period, management with AADs and/or electrical cardioversion is permitted. In addition, all patients presenting with AF at the 2-month visit, irrespective of symptom burden, will be referred for early electrical cardioversion, so that the majority of patients enter the rhythm analysis period in SR. Five-day ECG monitoring will be performed at 3, 6, 9, and 12 months starting on the day of randomization, and every 6 months thereafter.

ENDPOINTS Primary endpoint The primary outcome is freedom from any documented AF, AT, or AFL without antiarrhythmic drug therapy, cardioversion, or redo ablation, through 12 months after randomization, following the protocol-defined blanking period.

Secondary endpoints

  • AF/AFL/AT burden during the first 12 months after randomization
  • Quality of life assessment using the AFEQT questionnaire
  • AF-related clinical outcomes, i.e., emergency visits or hospitalizations due to documented recurrence of AF/AFL/AT during the whole study course
  • Major Adverse Cardiovascular Events (MACE), a composite of cardiovascular death, stroke, myocardial infarction, or hospitalization for heart failure during the whole study course
  • A composite of pre-specified procedure-related SAEs within 7 days after the procedure, including clinically relevant delayed SAEs adjudicated as related to the index ablation procedure Endpoint definition Primary endpoint: An episode of AF/ AT/AFL is defined as either (1) a recording demonstrating at least 30 seconds of continuous interpretable signal during Holter monitoring performed at 3, 6, 9, or 12 months, or (2) a 12-lead ECG demonstrating the arrhythmia throughout the entire tracing, with at least 10 seconds of continuous interpretable signal during scheduled or emergency visits.

In addition to a documented AF/AT/AFL episode as defined above, treatment failure (a primary endpoint event) will also be considered to have occurred if, after the end of the blanking period, any of the following occurs: (a) initiation or continuation of a Class I or Class III antiarrhythmic drug, or of sotalol, irrespective of the indication; (b) electrical cardioversion for AF/AT/AFL; (c) a repeat (redo) ablation for AF/AT/AFL. Beta-blockers and calcium-channel blockers do not constitute treatment failure. The date of the earliest of these events, or the qualifying documented episode will be considered the date of the primary endpoint.

Secondary endpoints AF/AT/AFL burden Overall AF burden will be calculated for each patient as the percentage of total analysable monitoring time across protocol-specified Holter recordings during the first 12 months after randomization spent in AF, AT, or AFL. AF/AT/AFL burden will also be calculated separately at each scheduled Holter assessment at 3, 6, 9, and 12 months.

Quality of life: quality of life will be assessed using the standardized AFEQT (Atrial Fibrillation Effect on QualiTy-of-life) questionnaire at the baseline visit and at the 12-month follow-up visit after randomization. The 12-month score is the endpoint and is analysed with the baseline score as a covariate.

AF-related clinical outcomes are defined as any emergency visits or hospitalizations due to recurrence of AF/AFL/AT during the entire study period. Importantly, the arrhythmia must be documented by ECG (12-lead ECG or other ECG tracing obtained by emergency medical services). Emergency visits due to palpitations without an ECG-documented arrhythmia will not be considered an endpoint.

MACEs are defined as a composite of cardiovascular death, stroke, myocardial infarction, or hospitalization for heart failure during the entire study period.

Cardiovascular death will be defined as death resulting from a cardiovascular cause, including myocardial infarction, heart failure, sudden cardiac death, stroke, pulmonary embolism, cardiovascular procedures, or other vascular causes, and includes any death for which a cardiovascular cause cannot be definitively excluded (sudden unwitnessed death).

Stroke will be defined as an acute neurological deficit of vascular origin lasting ≥24 hours or resulting in death, confirmed by neuroimaging (CT or MRI) demonstrating cerebral infarction or intracranial haemorrhage, or by clinical assessment when imaging is not available, and not explained by an alternative non-vascular diagnosis.

Myocardial infarction will be defined according to ESC criteria as a rise and/or fall in cardiac troponin with at least one value above the 99th percentile upper reference limit, together with clinical, electrocardiographic, imaging, or angiographic evidence of myocardial ischaemia. However, an isolated procedure-related elevation in cardiac troponin following ablation procedure, in the absence of other evidence of myocardial ischaemia, will not be considered myocardial infarction.

Hospitalization for heart failure will be defined as an unplanned admission to a hospital with a primary diagnosis of heart failure, characterized by worsening symptoms and/or signs of heart failure, requiring at least an overnight in-hospital stay and necessitating initiation or escalation of heart failure-directed treatment, including but not limited to intravenous diuretics, vasodilators, inotropes, or mechanical circulatory or ventilatory support. Hospitalization for heart failure may, but does not necessarily have to, be associated with recurrence of AF/AT/AFL.

Procedure-related SAEs: list of pre-specified procedure-related SAEs is provided below. Clinically relevant SAEs occurring beyond the predefined 7-day safety window (e.g., atrio-oesophageal fistula or delayed cardiac tamponade) will be assessed for their potential relationship to the index ablation procedure. Events adjudicated as procedure-related will also be included in the safety endpoint.

All AF-related outcomes, MACEs and procedure-related SAEs will be assessed by the Clinical Event Committee (CEC), whose members will be unaware of treatment allocation; the adjudicated classification will be used in all analyses. Criteria under which initiation of antiarrhythmic therapy, cardioversion or repeat ablation constitutes a primary endpoint event are pre-specified in Endpoint section.

Data management A tailor-made website will be developed for the study. Each participating medical centre will have access to a dedicated section of the website (data entry and randomization).

Sample size calculation We assume that 55% of patients in the PVI-only group will achieve freedom from AF/AT/AFL during the first year of follow-up. In contrast, freedom from AF/AFL/AT in the PVI-plus group is expected in at least 68% of patients. These proportions correspond to a hazard ratio of 0.645 (log 0.68 / log 0.55) for AF/AT/AFL recurrence in the PVI-plus group as compared with the PVI-only group, assuming proportional hazards over the follow-up period.

Because the primary analysis is a time-to-event comparison using the Kaplan-Meier method and the stratified log-rank test, the sample size was derived from this hazard ratio by the method of Schoenfeld. A hazard ratio of 0.645 requires 164 primary-endpoint events to provide 80% power to detect a between-group difference at a two-sided alpha level of 0.05. With 12-month recurrence probabilities of 45% in the PVI-only and 32% in the PVI-plus group (a pooled probability of 38.5%), a total of 426 patients (213 per group) completing 12 months of follow-up are expected to yield those 164 events. Allowing for 5% of patients to be lost before the 12-month assessment and, conservatively, to contribute no events, a total of 450 patients (225 per group) will be randomized. The calculation was performed in R version 4.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

Statistical analysis and methods Analyses of the primary and secondary endpoints follow the intention-to-treat principle. All tests are two-sided at a significance level of 0.05 and all confidence intervals are two-sided at the 95% level.

The intention-to-treat population comprises all randomized patients, analysed according to the treatment assigned and irrespective of the procedure performed, of adherence to the protocol or of withdrawal from follow-up. It is the primary analysis population for the primary endpoint and for all secondary efficacy endpoints.

Primary endpoint analysis Treatment failure is defined in the Endpoint definition section; the date of the earliest qualifying event is the date of the primary endpoint. All components of the primary endpoint will be adjudicated either by the Clinical Events Committee or blinded ECG Holter analysis team without knowledge of treatment allocation, and the adjudicated value will be used in the analysis.

Day 0, the end of the blanking period, delayed entry and the handling of patients in whom the protocol-mandated cardioversion fails are defined in the Blanking period section and apply to all analyses.

Where AF/AT/AFL is documented by rhythm monitoring initiated at the 12-month assessment, the event date used is the earlier of 365 days after randomization and the actual date of the episode, so that episodes identified at the 12-month assessment are counted even where the assessment took place after day 365 but within its ±14-day window.

Patients without a qualifying event are censored at the last date on which all components of the primary endpoint could be ascertained, that is, the later of the last available rhythm assessment and the last clinical contact at which antiarrhythmic drug use, cardioversion and redo ablation status were recorded; no follow-up time is credited beyond that date. Patients who die without a qualifying event are censored at the date of death and their number reported by arm; given the small number of deaths anticipated over 12 months, no competing-risk analysis is planned.

Freedom from treatment failure will be estimated in each arm by the Kaplan-Meier method, with standard errors from Greenwood's formula and two-sided 95% confidence intervals based on the log-log transformation. The following hypothesis will be tested by a two-sided log-rank test at α = 0.05, stratified by the three randomization factors (sex, left atrial diameter, age category):

H0: S_PVI-plus(t) = S_PVI-only(t) for all t between the end of the blanking period and 12 months after randomization Ha: S_PVI-plus(t) ≠ S_PVI-only(t) for some t between the end of the blanking period and 12 months after randomization

where S(t) denotes the probability of freedom from treatment failure. Because patients enter the risk set at the end of their individual blanking period, the statistic will be obtained as the score test of the corresponding stratified Cox model on left-truncated data, which is numerically identical to the stratified log-rank test.

The treatment effect will be estimated as a hazard ratio from the same stratified Cox model with a 95% confidence interval, interpreted as an average effect over the follow-up period. The proportional hazards assumption will be examined on scaled Schoenfeld residuals, and the difference in restricted mean survival time at 12 months reported as a supportive measure of effect. The Kaplan-Meier estimates of freedom from treatment failure at 12 months and their difference with a 95% confidence interval, which is the quantity for which the sample size was calculated, will be reported as the primary descriptive summary; the curves will be displayed from randomization with the numbers at risk at each time point. Supportive analyses comprise the unstratified log-rank test, so that the marginal comparison is also on record, and the primary analysis additionally stratified by study site.

The stratification factors used in all stratified analyses are those recorded by the randomization system at the time of allocation. Any discrepancy between these and the final clinical values recorded in the case report form will be reported.

Secondary endpoint analyses AF/AT/AFL burden. The overall burden is the proportion of analysable monitoring time spent in AF, AT or AFL across all protocol-specified Holter recordings obtained during the first 12 months after randomization, computed for each patient as the total time in AF/AT/AFL divided by the total analysable monitoring time. A recording contributes only if at least 24 hours of it are analysable, and a patient contributes only if at least 72 hours are analysable across all scheduled recordings; patients below that threshold are treated as missing for this endpoint and their number is reported by arm with reasons.

AF burden after ablation is strongly zero-inflated and, in patients whose persistent AF recurs, also has a mass near 100%, so it is neither approximately normal nor a location shift of a common distribution. The primary comparison is therefore the non-parametric relative effect, the probability that a randomly selected patient in the PVI-plus arm has a lower burden than a randomly selected patient in the PVI-only arm, with ties counted at one half. It is reported with a two-sided 95% confidence interval and tested against one half by the Brunner-Munzel test, which does not require the two distributions to have the same shape and tolerates the extensive ties that the zero-inflation produces; if the asymptotic test is in doubt, the p-value is obtained by studentized permutation. Burden is summarized by arm as the median with interquartile range, the mean with standard deviation, and the proportion of patients with 0%, above 0% to 1%, above 1% to 10%, above 10% to 50%, and above 50%.

Quality of life The quality-of-life endpoint is the AFEQT overall score at 12 months, analysed using analysis of covariance (ANCOVA) with the 12-month AFEQT score as the dependent variable, treatment group as the main factor, and the baseline AFEQT score as a covariate. The adjusted between-group difference with the corresponding 95% confidence interval will be reported and interpreted against a minimal clinically important difference of 5 points.

AF-related clinical outcomes, MACE, and procedure-related SAE AF-related clinical outcomes and MACEs will be analysed using Kaplan-Meier estimates and Cox proportional hazards regression models, with treatment group as a covariate. The proportion of patients experiencing at least one pre-specified procedure-related SAE will be compared between treatment groups using Fisher's exact test.

Formal testing of the secondary endpoints is conditional on the primary endpoint reaching statistical significance, and then proceeds in the pre-specified fixed sequence (1) overall AF burden, (2) quality of life, (3) AF-related clinical outcomes, (4) MACEs, stopping at the first endpoint that does not reach the two-sided 0.05 level.

The composite of pre-specified, procedure-related SAEs is reported unconditionally with risk differences, 95% confidence intervals and nominal p-values; it is not part of the hierarchy.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • persistent atrial fibrillation
  • catheter ablation
  • pulmonary vein isolation
  • pulsed-field ablation
  • radiofrequency ablation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • symptomatic persistent AF
  • ≥1 episode of persistent AF in the last 12 months
  • signed

Exclusion criteria

Exclusion Criteria:

  • first-manifested AF, paroxysmal AF, long-standing persistent AF, permanent AF
  • SR on admission without Class I/III AADs
  • AF of secondary cause (e.g. hyperthyroidism)
  • any previous LA ablation
  • severe valvular disease (mitral valve insufficiency ≥3+, moderate or severe aortic stenosis) or history of valvular surgery or intervention
  • ≤40%
  • pulmonary hypertension (estimated systolic pulmonary artery pressure ≥40 mm Hg)
  • symptomatic coronary artery disease
  • pregnancy
  • LA anteroposterior diameter ≥55 mm
  • ≥40 kg/m2
  • age ≥80 years
  • chronic kidney disease stage 3b or higher
  • to anticoagulation
  • general contraindications of catheter ablation
  • \<2 years due to other comorbidities
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    PVI-plus group

    Patients allocated in the PVI-plus arm will undergo comprehensive ablation consisting of pulmonary vein isolation, roof line, inferior line, mitral ishtmus line, horizontal line in the left atrium, intercaval line, and cavotricuspid line in the right atrium.

    Procedure: PVI-plus

  • Active comparator
    PVI-only group

    Patients allocated in the PVI-only arm will undergo pulmonary vein isolation without any additional ablation lesions.

    Procedure: PVI-only

Interventions

  • ProcedurePVI-plus

    Patients randomized to the PVI-plus arm will undergo PVI plus linear lesions (roof, bottom line, lateral or anterior MI line, and septal line in the LA; intercaval line and cavotricuspid line in the RA).

  • ProcedurePVI-only

    Patients randomized to the PVI-only arm will undergo only PVI.

06

What researchers measure

Primary outcomes

  1. Freedom from AF, AT and AFL

    An episode of AF/ AT/AFL is defined as either (1) a recording demonstrating at least 30 seconds of continuous interpretable signal during Holter monitoring performed at 3, 6, 9, or 12 months, or (2) a 12-lead ECG demonstrating the arrhythmia throughout the entire tracing, with at least 10 seconds of continuous interpretable signal during scheduled or emergency visits. In addition to a documented AF/AT/AFL episode as defined above, treatment failure (a primary endpoint event) will also be considered to have occurred if, after the end of the blanking period, any of the following occurs: (a) initiation or continuation of a Class I or Class III antiarrhythmic drug, or of sotalol, irrespective of the indication; (b) electrical cardioversion for AF/AT/AFL; (c) a repeat (redo) ablation for AF/AT/AFL. Beta-blockers and calcium-channel blockers do not constitute treatment failure.

    Time frame: 12 months

Secondary outcomes

  1. AF/ AT/AFL burden

    The percentage of total monitoring time spent in atrial fibrillation, atrial tachycardia, or atrial flutter during Holter recordings at 3, 6,9 and 12 months.

    Time frame: 12 months

  2. AF-related clinical outcomes

    Number of patients with a need for any emergency visits or hospitalizations due to recurrence of AF/AFL/AT during the entire study period. Importantly, the arrhythmia must be documented by ECG (12-lead ECG or other ECG tracing obtained by emergency medical services). Emergency visits due to palpitations without an ECG-documented arrhythmia will not be considered an endpoint.

    Time frame: 36 months

  3. Quality of life

    Quality of life: quality of life will be assessed using the standardized AFEQT (Atrial Fibrillation Effect on QualiTy-of-life) questionnaire at the baseline visit and at the 12-month follow-up visit after randomization. The 12-month score is the endpoint and is analysed with the baseline score as a covariate.

    Time frame: 12 months

  4. MACE

    Major adverse clinical outcomes (MACE), a composite of cardiovascular death, stroke, myocardial infarction, or hospitalization for heart failure during the whole study course

    Time frame: 36 months

  5. A composite of procedure-related SAEs

    Clinically relevant SAEs occurring beyond the predefined 7-day safety window (e.g., atrio-oesophageal fistula or delayed cardiac tamponade) will be assessed for their potential relationship to the index ablation procedure. Events adjudicated as procedure-related will also be included in the safety endpoint. All AF-related outcomes, MACEs and procedure-related SAEs will be assessed by the Clinical Event Committee (CEC), whose members will be unaware of treatment allocation; the adjudicated classification will be used in all analyses

    Time frame: 1 month

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared upon reasonable request e..g for IPD metaanalysis etc.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.

Of 794 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 42 months is close to that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2026
First posted
Feb 20, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07424326
Collaborators
Institute for Clinical and Experimental Medicine, University Hospital Olomouc, Cardiocenter Podlesí, Trinec, Czech Republic, Faculty Hospital Kralovske Vinohrady
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Jun 1, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 24, 2026

Study contacts

Pavel Osmancik
Contact
pavel.osmancik@gmail.com
00420-267163029

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion